Ibudilast · MN-166, IBUD

What is Ibudilast?

Ibudilast is an orally bioavailable phosphodiesterase inhibitor targeting PDE-3, -4, -10, and -11 with anti-inflammatory and neuroprotective properties. It crosses the blood-brain barrier and reduces pro-inflammatory cytokines while promoting neurotrophic factors. It is studied in amyotrophic lateral sclerosis, substance use disorders, and opioid dependence.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

MN-166, IBUD, AV-411, Pinatos

Drug type

Small molecule

Targets

phosphodiesterase-3, phosphodiesterase-4, phosphodiesterase-10 (PDE10A), phosphodiesterase-11, macrophage migration inhibitory factor (MIF) (secondary target), toll-like receptor-4 (TLR4) (secondary target)

Mechanism

Inhibitor of phosphodiesterase-3, phosphodiesterase-4 and phosphodiesterase-10 (PDE10A)

Pathways

PI3K/Akt, neuroinflammation, immune suppression

Therapy area

Neurology

Developer

MediciNova (MNOV)

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 2/3

UNII

M0TTH61XC5

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Amyotrophic Lateral SclerosisAlcohol Use DisorderMethamphetamine-dependenceOpioid AbuseOpioid DependenceSubstance Abuse

More from MediciNova

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT01740414
• ClinicalTrials.gov NCT03594435
• ClinicalTrials.gov NCT04057898

Updated Oct 3, 2026. Something wrong or missing? Report it on the MNOV page.